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Abstract: 
Background:  
In light of the opioid epidemic, reducing excess prescription quantities while tailoring to patient 
need is key. We previously created an opioid prescribing guideline using retrospective 
institutional data to satisfy the majority of patients’ opioid needs following inpatient colorectal 
surgery. 
Objective: 
This study sought to prospectively validate an institutional prescribing guideline based on 
previously-defined opioid consumption patterns following inpatient colorectal operations. 
Methods: 
We carried out  a cohort study comparing opioid prescribing and consumption patterns before 
(7/18 – 1/19) and after (9/19 – 2/20) adoption of a tiered opioid prescribing guideline for 
inpatient elective colorectal operations (colectomies, proctectomies, and ostomy reversals) at a 
single tertiary care medical center. Opioid use was quantified as Equianalgesic 5mg Oxycodone 
Pills (EOP), and patients were grouped in three tiers based on opioid consumption in the 24-
hours prior to discharge: Tier 1 (0 EOP), Tier 2 (0.1-3 EOP), and Tier 3 (>3 EOP). Our guideline 
recommended maximum prescriptions of 0 EOP for Tier 1, 12 EOP for Tier 2, and 30 EOP for 
Tier 3. 
Results: 
The study included 100 patients before and 101 after guideline adoption. Demographic and 
operative variables were similar before and after guideline adoption. Guideline adherence was 
85%. Overall, there was a 41% reduction in mean prescription quantity and 53% reduction in 
excess pills per prescription with no change in opioid consumption or refill rates. 
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Conclusion: 
Adoption of a tiered opioid prescribing guideline significantly reduced opioid prescription 
quantity with no change in consumption or refill rates. Standardization of discharge prescriptions 
based on patient consumption in the 24 hours prior to discharge may be an important step 
towards minimizing excess prescribing. 
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Pain management; Colorectal Surgery; Post-operative pain; Opioid; Narcotic 
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Chapter I: Introduction 
Opioid History and Pharmacology  
Opiate alkaloids have been used by humans for thousands of years to treat pain.1 Harvested 
from the resin of the opium poppy (Papaver somniferum), these molecules have been 
commercially extracted to produce morphine since the 1820s.2 The first synthetic opioids were 
generated around 100 years ago.2 While the term “opiate” generally refers to alkaloids derived 
from the opium poppy,  such as morphine and codeine, the term “opioid” refers to all compounds 
that bind to the opioid family of receptors including semi-synthetic opiates such as heroin and 
oxycodone, and synthetic opioids such as methadone and fentanyl.3 The term “narcotic” is a legal 
definition referring to opioids as well as other non-opioid drugs.3  
Although several types of opioid receptors exist, all opioids achieve their primary analgesic 
effects by binding to the µ-opioid receptor.1 Mu-opioid receptors are located in the central and 
peripheral nervous system.1 Activation of µ-opioid receptors suppresses key components of the 
pain pathway, but also suppress respiratory centers in the brainstem, motility in the GI tract, and 
activate nausea in the chemoreceptor trigger zone of the brainstem.2 Opioids have other adverse 
effects including development of hyperalgesia, tolerance, and addiction which are exacerbated 
with repeated or prolonged exposure. Despite considerable investment into alternative pathways 
to treat pain, opioids remain the most frequently used medication to treat severe pain and one of 
the most commonly prescribed medications in the U.S.2 
 
Opioid Prescribing in the United States 
Opioid prescriptions and overdose deaths in the U.S. have risen dramatically over the past 
three decades.4, 5  The number of opioid overdose deaths have quadrupled from 2000 to 2015 and 
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prescription rates hit a peak of 81.3 prescriptions per 100 residents in 2012.4, 5 Since that time both 
prescriptions and overdoses related to this drug have been declining, yet our society remains in the 
midst of an opioid epidemic.6  
Opioid medications have a high potential for abuse, diversion, and dependence.7-10 
According to the 2018 National Survey on Drug Use and Health, 4% of adults in the U.S. reported 
misuse of opioids in the past year.11 Among the respondents, over half obtained opioid medications 
through diversion from a friend or family member, approximately 2 in every 5 individuals  misused 
pills from a legitimate prescription, while only 7% reported obtaining the medications from a drug 
dealer.11 Excess pills stored in homes are an important source of diversion through sale or theft.8, 
9, 12  
Surgeons play an important role in combating the opioid epidemic since it is well 
established that U.S. surgeons overprescribe opioids for post-operative pain.12 A 2017 systematic 
review of surgical opioid prescribing found that 42-71% of prescribed pills went unused.10 
Overprescribing after surgery not only increases the potential for diversion, but can contribute to 
misuse and dependence. The quantity of pills prescribed after surgery is strongly associated with 
the rate of misuse.9 Additionally, the risk of opioid naïve surgical patients developing long-term 
opioid use is highly correlated with the quantity of the initial opioid prescription.13 In opioid naïve 
surgical patients, the rate of persistent opioid use after one year is between 6-8%.14, 15 A reduction 
in excess prescribing after surgery may help combat opioid diversion and dependence. 
 
Current Prescribing Guidelines 
 A key challenge to improving post-surgical opioid prescribing on the national scale has 
been a lack of consensus on appropriate prescribing targets for individuals or populations. Most 
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prescribing guidelines fail to delineate specific prescription quantities. 16-18  The Centers for 
Disease Control recommend not exceeding a 7-day supply after surgery but does not specify 
dosages or methods to determine what quantity constitutes a 7-day supply.16 Massachusetts 
guidelines state that dosing should be the minimum dosage necessary and the duration should be 
as short as possible.17  Guidelines from pain and anesthesia societies, such as the American Pain 
Society, the American Society of Regional Anesthesia and Pain Medicine, and the American 
Society of Anesthesiologists are similarly vague and lack specific prescription quantities.18 The 
Michigan Opioid Prescribing Engagement Network is the only state-sponsored group to provide 
procedure-specific prescription guidelines for opioids and recommends the following for 
colorectal operations: 0-10 pills after laparoscopic colectomies and 0-15 pills after open 
colectomies or ostomy reversals.19 While these recommendations are likely adequate for most 
patients who undergo these surgeries, they do not account for the variable needs of individual 
patients, in particular, those patients who have high requirements for pain medication at the time 
of discharge.  
Studies that have examined the association between pre-discharge opioid requirements 
with consumption after discharge have provided an alternative approach to post-surgical opioid 
prescribing.20, 21 In a study of inpatient general surgery procedures, Hill et al.20 suggest a 
prescribing algorithm for inpatient general surgery operations that ties discharge prescribing to the 
quantity of opioids consumed in the 24-hours prior to discharge; prospective evaluation of this 
algorithm remains needed. However, since this algorithm was based on a surgical population that 
included bariatric, foregut, pancreatectomy, and ventral hernia operations, it may not be applicable 
to colorectal surgery population. A tiered opioid prescribing guideline based on a similar concept 
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has been proposed and validated for gynecologic operations.21 There have been no similar studies 
performed in the colorectal surgery population. 
 
Development of a Tiered Opioid Prescribing Guideline for Colorectal Operations 
 In order to reduce variability and excess prescribing after colorectal operations, the 
Division of Colon and Rectal Surgery at the University of Massachusetts Medical School sought 
to develop a simple opioid prescribing guideline that would couple discharge prescriptions to 
opioid consumption in the day prior to discharge for patients undergoing major elective inpatient 
colorectal operations. To develop this guideline, we analyzed the opioid consumption patterns of 
100 patients undergoing inpatient colorectal operations (colectomies, proctectomies, and ostomy 
reversals) between July 2018 and January 2019 performed by five board certified colorectal 
surgeons at our single academic institution (unpublished data). We found wide variability and 
excessive prescribing, with over 60% percent of prescribed pills left over and one-half of patients 
taking no pills after discharge.  
Based on these findings, we developed a prescribing guideline designed to satisfy the 
needs for the majority of patients. To facilitate standardized dosing language, all opioid dosages 
opioid dosages were converted to Equianalgesic 5-mg Oxycodone Pills (EOP). The prescribing 
guideline had three tiers based on opioid consumption in the 24-hours prior to discharge: Tier 1 
(0 EOP), Tier 2 (0.1–3 EOP), and Tier 3 (3.1 EOP or greater). The cut-point for each tier was 
determined post hoc to maximize equal distribution between tiers. The prescribing 
recommendation for Tier 1 was set at 0 EOP since less than 25% of patients in Tier 1 consumed 
any additional opioid pills as an outpatient. For Tier 2 and Tier 3, the prescribing 
recommendation was set at the 85th percentile of opioid consumption based on similar 
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methodology published by Hill et al.20 Our final guideline recommended a maximum discharge 
prescription for each tier: 0 EOP for Tier 1, 12 EOP for Tier 2, and 30 EOP for Tier 3 (Figure 1). 
By applying the prescription recommendations to the historical dataset, we calculated that the 
proposed guideline could reduce prescribed pills by as much as 45% and excess pills by as much 
as 73%. The guideline was adopted at our institution in August 2019. 
 
Specific Aims: 
The primary aim of this prospective study was to examine changes in opioid prescribing and 
consumption patterns after implementation of a tiered opioid prescribing guideline for inpatient 
colorectal operations at a single academic medical center. We secondarily sought to determine 
the rate of guideline adherence among prescribers. 
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Chapter II: Methods 
Adoption of the Prescribing Guideline 
In August 2019, we presented the main findings from our guideline development to the 
surgical residents during time set aside for weekly resident education. We also provided 
education on the new prescribing guidelines to the physician assistants involved with inpatient 
management of patients who were undergoing colorectal surgery. The guidelines were 
distributed on laminated reference cards to all residents and physician assistants and a poster 
detailing the guidelines was posted in the resident work area. Data collection was started in 
September 2019, one-month after guideline adoption to allow a transition period for full 
implementation and adoption of the guidelines. A monthly email summarizing the prescribing 
guideline was distributed to all members of the colorectal surgery service for the duration of the 
study, coinciding with scheduled resident turnover. 
 
Study Population 
 The study population was determined using the inclusion and exclusion criteria that had 
been used in our previous guideline development study. After guideline adoption, all adult patients 
who underwent major elective colorectal operations at a single academic medical center performed 
by four board-certified colorectal surgeons between September 2019 and February 2020 were 
eligible. Major colorectal operations included in the study were partial colectomy, proctectomy, 
total abdominal colectomy, total proctocolectomy, ileostomy takedown, and colostomy takedown. 
Patients were excluded from the present study if they had a hospital stay less than 48 hours, were 
taking opioid medication within 30 days prior to surgery, or if opioid consumption data were not 
documented in the first post-operative clinic note. Patients were also excluded if they were 
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discharged to an inpatient facility (inpatient rehabilitation center, skilled nursing facility, or long-
term acute care hospital) because many of these facilities have staff physicians who prescribe 
patient medications during their facility stay and thus these patients are not provided with an opioid 
prescription at hospital discharge. All patients received standard of care during their 
hospitalization. A printed after-visit summary is provided to patients at the time of discharge, 
which was reviewed by the discharging nurse and provides instructions to expect pain for 2 to 3 
weeks after surgery and to alternate using over-the-counter Tylenol and ibuprofen for pain, 
reserving opioid medications for breakthrough pain.  
 
Data Collection 
 Data collection was performed using the same methodology that had been utilized in our 
previous guideline development study. For each patient, the electronic medical record (EMR) was 
reviewed and selected sociodemographic and clinical characteristics were extracted including 
patient demographic characteristics, medical history, prior opioid use, alcohol and drug use, and 
currently prescribed medications. Prior opioid prescriptions were reviewed in the EMR and opioid 
exposure status was determined for each patient in the following: opioid naïve defined as no 
documented opioid prescription within 1 year prior to surgery, opioid exposed defined as 
documented opioid prescription within 1 year, but greater than 30 days prior to the operation. 
 Operative procedure characteristics were collected from the EMR including procedure 
type, surgical approach, and operative time. Operative approach was categorized as laparoscopic, 
robotic, or open.  Post-operative variables extracted were length of stay and 30-day complications. 
Post-operative complication data were collected for occurrences of ileus, urinary tract infection, 
urinary retention, surgical site infection, deep venous thrombosis, pneumonia, chronic obstructive 
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pulmonary disease exacerbation, congestive heart failure exacerbation, myocardial infarction, 
unplanned intensive care unit admission, delirium, anastomotic leak, reoperation, and unplanned 
readmission occurring within a 30-day postoperative period; a composite any-complication 
variable was created for purposes of analysis.  
Post-operative opioid data collected were: 24-hour prior-to-discharge opioid consumption, 
prescription quantity (opioid and non-opioid pain medications), quantity of opioid pills consumed 
prior to the first post-operative appointment, pain in clinic (on a scale of 0 to 10), and opioid refills 
within 30 days of hospital discharge. Guideline adherence was defined as a prescription that less 
than or equal to the maximum recommended prescription quantity for each tier. The six-month 
study after guideline adoption was a priori divided into two-month prescribing periods (months 1-
2, 3-4, and 5-6) to evaluate potential differences in medication adherence and practice adoption 
over time. The opioid prescriber was categorized as either off-service resident, surgical resident, 
fellow, physician assistant, or surgeon. For cases in which no opioid prescriptions were given, the 
medical provider who signed the discharge paperwork was recorded as the prescriber. Quantity of 
opioid pills consumed was self-reported by the patient at the time of their first post-operative visit 
and recorded by the clinic provider. To reduce reporting bias, a waiver of consent was obtained 
from Institutional Review Board at the University of Massachusetts Medical School and patients 
were not made aware of the study protocol. 
 
Conversion to Equi-analgesic 5mg Oxycodone Pills 
 Oral opioid dosages were converted to EOP (i.e. 1 EOP = 5 mg oxycodone = 7.5 mg 
morphine equivalent) based on the opioid conversion factors published by the Centers for 
Medicare and Medicaid Services.22 Conversion factors published by University of North Carolina 
   
 
24
Health Care Guidelines23 were used for intravenous (IV) dosages because these were not available 
from the Centers for Medicare and Medicaid Services. 
 
Sample Size Calculation 
 Sample size calculation was performed for comparison of two independent means using 
historical institutional data for mean opioid prescription quantity and the accompanying standard 
deviation. Application of the proposed prescribing guideline to the historical sample would have 
reduced the mean prescription quantity by 45%. We assumed an expected guideline adherence of 
70% based on data from a prior study of prescription guideline adoption in an academic general 
surgery practice.24 Therefore, we based our estimate on a 32% reduction in mean prescription 
quantity (study mean 12.0 EOP). We performed a sample size calculation for comparing two 
means, which resulted in a sample size of 57 in each group. Based on our prior guideline 
development study, we expected 36% of the screened population to be excluded for pre-specified 
factors, so we anticipated needing to screen a minimum of 89 patients to detect a clinically 
meaningful difference in mean prescription quantity. We decided on a 6 month period of data 
collection to ensure that we would meet this minimum number of patients to be studied.  
 
Data Analysis 
 Univariate analysis was performed comparing data collected after guideline adoption to a 
historical comparison group collected before guideline adoption. For univariate analysis, Pearson’s 
chi-square and Fisher’s Exact tests were used to compare categorical variables, while ANOVA 
was used to compare continuous variables. Subgroup analysis for guideline adherence was 
compared between Tiers 1-3, prescriber, and prescribing period using Fisher’s Exact test. 
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Subgroup analysis for opioid prescribing and consumption patterns was performed between Tiers 
1-3 using ANOVA and proportion of patients requiring a refill using Fisher’s Exact test.  
A multivariable logistic regression analysis was performed to model factors independently 
associated with requiring an opioid refill. For these models, a stepwise multivariable logistic 
regression was performed starting with the inclusion of all demographic and operative variables 
until the final model was limited to variables that met a p < 0.05 inclusion threshold. Opioid 
exposure status, procedure category, prescribing tier, length of stay, and ostomy creation were a 
priori determined to be clinically relevant and forced into the stepwise logistic regressions. We 
calculated area under the curve (AUC) to evaluate model fit. All statistical analyses were 
performed using STATA software (version 15.1, StataCorp, College Station, TX). 
 
Ethical Considerations: 
The study was approved by the Institutional Review Board at the University of 
Massachusetts Medical School. The study was deemed low risk and a waiver of consent was 
granted. 
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Chapter III: Results 
Baseline Study Population Characteristics  
During the 6-months after guideline adoption, a total of 155 patients underwent major 
inpatient colorectal operations (partial colectomy, proctectomy, total abdominal colectomy, total 
proctocolectomy, ileostomy takedown, and colostomy reversal) at our medical center. Of these,  
54 patients were excluded: 16 for an emergency procedure, 3 were discharged to an inpatient 
facility, 16 for recent opioid prescription within 30 days prior to surgery, and 20 for missing 
follow-up opioid consumption data. Data from 101 patients were analyzed after guideline 
adoption (Figure 1).  This is similar to the historical comparison group in which 157 patients 
underwent major inpatient colorectal operations at our institution between July 2018 and January 
2019 with 57 patients excluded and the data from 100 patients analyzed(Figure 1).  
After guideline adoption, the average age of the study population was 64 years and 55% 
were female (Table 1). The population was predominantly white (89%) and English was the 
primary language for 91% of patients. The majority (68%) of patients underwent minimally 
invasive procedures and a diverting ostomy was created in 19% of cases (Table 2). The mean 
length of stay was 4.5 days with half of all patients discharged in 3 days or less. Most patients 
(70%) did not require visiting medical services at home after discharge (Table 2). 
In comparing the study population after guideline adoption to the historical dataset 
collected during guideline development, a significantly greater proportion of patients after 
guideline adoption had a high American Society of Anesthesiologists classification (ASA III or 
IV) compared to before adoption indicating more severe baseline comorbidities (p = 0.001; Table 
1). There was also a higher rate of any-readmission within 30-days after guideline adoption (2% 
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vs 13%; Table 2). All other patient, operative, hospitalization, and post-operative complications 
characteristics were similar before and after guideline adoption. 
 
Inpatient Medication Use 
 Receipt of hospital administered non-opioid analgesic medications were not collected in 
before guideline adoption and, therefore, not available for comparison. After guideline adoption, 
the pain regimen on post-operative day one consisted of IV opioids (93%), oral acetaminophen 
(93%), and IV ketorolac (64%) for the majority of patients, while only 8% were taking oral 
opioids. Other non-opioid analgesic medications administered on the first post-operative day 
included gabapentin for 22%, transdermal lidocaine patch for 14%, and oral non-steroidal anti-
inflammatory medications for 2%. No patients received IV acetaminophen. 
 
Guideline adherence 
 There was 85% adherence to the discharge opioid prescribing guideline as measured by 
prescriptions that were less than or equal to the maximum guideline recommendation for each 
tier (Table 3). Guideline adherence did not differ by prescribing tier, operating surgeon, or 
prescribing period. There was greater than 90% adherence to the guideline by surgical residents 
and physician assistants, but there was significantly lower adherence by non-surgical residents 
rotating on the colorectal surgery service (90% vs 73%, p = 0.04; Table 3). 
 
Prescriptions at hospital discharge 
 After guideline adoption, the mean quantity of opioids prescribed was 10.3 EOP overall, 
but was significantly different for each prescribing tier: 1.8 EOP for Tier 1, 12.0 EOP for Tier 2 
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and 25.7 EOP for Tier 3 (Table 4). The mean quantity of opioids prescribed was significantly 
lower after guideline adoption for Tier 1 (1.8 EOP vs 15.7, p < 0.001) and for the total group 
(10.3 EOP vs 17.5, p <0.001) compared to before guideline adoption but was not significantly 
different for those in either Tier 2 or Tier 3 (Table 4). Overall, there was a 43% reduction in 
opioids prescribed (Table 5). Among each prescribing tier, the largest reduction achieved was 
89% for patients classified in Tier 1, and a 25% reduction for those in Tier 2; patients in Tier 3 
showed an 8% increase in prescription quantity (Table 5).  
 
Opioid Consumption Patterns at First Post-Operative Visit 
 After guideline adoption, outpatient opioid consumption had an overall mean of 5.2 EOP, 
but consumption was significantly different between prescribing tier: 0.2 EOP for Tier 1, 5.6 
EOP for Tier 2, and 15.1 EOP for Tier 3 (p < 0.001; Table 4). Compared to before guideline 
adoption, opioid consumption in Tier 1 was lower after guideline adoption (0.2 EOP vs 2.5, p = 
0.01), but was not different for Tier 2, Tier 3, or the overall study population. The proportion of 
patients requiring a prescription refill for an opioid was 10% after guideline adoption compared 
to 15% before adoption (p = 0.27). The highest refill rate was seen in Tier 3 with 40% requiring 
a refill before guideline adoption and 28% after guideline adoption. Overall, there was a 52% 
reduction in excess pills left over with a reduction by 87% in Tier 1, 40% in Tier 2, and a 109% 
increase in Tier 3.  
 
Multivariable Models 
 During our prior guideline development study, there were 17 patients  (17%) who 
consumed more pills than would be prescribed according to the guideline. Using a stepwise 
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elimination procedure, a history of inflammatory bowel disease was the only variable that was 
significantly associated with an increased odds of consuming more than the prescription 
guideline (aOR 7.2, 95% CI 1.6-32.6) after adjustment for prescribing tier, opioid naïve status, 
procedure type, ostomy creation, length of stay, and prescription quantity. The model AUC was 
0.80.  
We applied the same stepwise elimination modeling procedure to the study cohort after 
guideline adoption to determine factors associated with requiring an opioid refill, which is 
analogous to consuming more than the prescription guideline. We found no independent 
variables remaining in the model. Among the forced exposure variables, prescribing tier was 
significantly associated with requiring a prescription refill after adjustment for opioid naïve 
status, procedure type, ostomy creation, length of stay, and prescription quantity. Patients in Tier 
3 had a 75-fold greater odds of requiring a prescription refill (aOR 75.2, 95% CI 2.6 – 2142) 
compared with those in Tier 1, while Tier 2 was not significantly different (aOR 3.9, 95% CI 
0.2- 62.9) from Tier 1 after adjustment for similar potentially confounding variables. The model 
AUC was 0.87. 
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Chapter IV: Discussion 
We found that a simple, three-tiered, opioid prescribing guideline can dramatically reduce 
discharge prescription quantities without increasing prescription refills. After guideline adoption, 
prescription quantities for opioids were reduced by 43% with the greatest reduction achieved for 
patients in Tier 1. Prescribing variability was also reduced within each prescribing tier. Adherence 
to the guideline was high among all prescribers with 85% of all prescribers following the 
prescribing recommendations. By tailoring discharge prescriptions to a patient’s opioid usage in 
the day prior to discharge, surgeons can better align discharge prescription quantity with a patient’s 
outpatient needs, thus limiting the overprescribing of these addictive medications. 
 
Rationale for a tiered prescribing algorithm 
We previously found that over 60% of prescribed opioids went unused after major 
colorectal operations at our institution, which is consistent with the prior literature in the general 
surgery population.10, 20 Outpatient opioid consumption varied greatly between individuals, but 
usage patterns emerged when patients were stratified by prior to discharge opioid requirements. 
This association between inpatient opioid requirements and outpatient consumption was similar to 
findings from prior studies of opioid consumption after major inpatient general surgery 
operations20 and gynecological operations21, and confirms findings from our own data prior to 
guideline adoption. Prescribing guidelines that fail to account for a patient’s opioid consumption 
prior to discharge will lead to excessive prescriptions for some patients and inadequate 
prescriptions for others. Our guideline takes into consideration prior to discharge opioid 
consumption by using a tiered prescribing system – no use (Tier 1), low use (Tier 2), high use (Tier 
3) – to better align prescription quantity with patients’ actual needs. 
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Impact of guideline adoption on opioid prescribing patterns 
After adoption of the tiered guideline, the number of excess pills was reduced by 51%. As 
expected, reductions in excess pills were different across prescribing tiers. The largest reduction 
was seen in Tier 1 where excess pills were dramatically reduced by 87%. This could be attributable 
to the fact that Tier 1 represents a group of patients who were unlikely to require outpatient opioids 
for pain control; however, prior to guideline adoption, most of these patients still received an 
average prescription of 16 EOP. By recommending no opioid prescription for patients in Tier 1, 
we were able to almost completely eliminate excessive prescriptions for one-half of all discharged 
patients. Similarly, we were able to reduce excess pills among patients in Tier 2 by 40% while 
simultaneously reducing prescription refills from 16% to 8%. This finding could be attributable to 
the wide variation and inconsistent quantities prescribed prior to guideline adoption, with a 
dramatic reduction in variability seen after guideline adoption. Prior studies have shown wide 
variability in prescribing among the general surgery population including one study that showed 
wide variability in prescription quantities among patients undergoing similar operations on the 
same acute care surgery service.20, 25, 26 Standardized prescription guidelines have been shown to 
decrease this prescribing variability.  For example, adoption of standardized prescribing guideline 
reduced the standard deviation of prescribed pills after laparoscopic colectomy from 17 to 7, 
inguinal hernia repair from 16 to 9, and partial mastectomy with sentinel lymph node biopsy from 
11 to 2.24 
We did find an increase in excess pills for patients in Tier 3, but this is not surprising given 
that the maximum recommended prescription quantity for this group (30 EOP) was greater than 
mean prescription before guideline adoption (24 EOP). The guideline was designed to meet the 
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needs for 85% of patients in this group. The recommended prescription for Tier 3 was greater than 
the historical mean because a substantial proportion of these patients were historically under-
prescribed opioids for pain control as evidenced by the 40% historical refill rate for patients in this 
tier. 
The Michigan Opioid Prescribing Engagement Network recommends 0-10 pills after 
laparoscopic colectomies and 0-15 pills after open colectomies or ostomy reversals.19 In our study, 
the mean outpatient consumption for Tier 3 exceeded the Michigan Opioid Prescribing 
Engagement Network recommendations. Therefore, consideration should be given to providing 
larger prescriptions for Tier 3 patients than recommended by the Michigan group. Tier 3 only 
represents a quarter of all surgical patients while Tiers 1 and 2 represent the majority (75%) of 
patients. The excess pills prescribed to Tier 3 were offset by a much greater reduction in pills for 
Tiers 1 and 2. The slight increase in prescription recommended for patients in Tier 3 was 
accompanied by clinically significant reduction in prescription refills from 40% to 28%. In total, 
these findings show that a tiered guideline based on a patient’s opioid requirement at the time of 
discharge is a pragmatic way to align prescription quantities with the actual needs of the patient. 
 
Guideline adherence 
The results of this study benefitted from high guideline adherence. Only 15% of 
prescriptions were written in excess of the adopted guideline. Our 85% guideline adherence rate 
is higher than the 68% adherence found in a before and after cohort study of guideline 
implementation in a general surgery practice using similar adherence measures24, but lower than 
the 96% adherence in a randomized controlled trial of guideline adoption after gynecologic 
operations.21 Prior to our guideline development there was no standardization for discharge opioid 
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prescribing at our institution. Guideline adherence may have been particularly effective in our 
study because once providers were provided with an evidence-based prescribing guideline, there 
was no substantial barrier to change. 
 
Study Strengths and Limitations 
 The main strength of this study is its prospective design which allows evaluation changes 
in opioid prescribing patterns after guideline adoption. Another strength of the study is that 
patients were blinded to the study design which helped to minimize potential observation bias.  
The study also included only patients undergoing select inpatient colorectal operations which 
provided a more homogenous population than previous studies of general surgery operations. 
This study had several limitations. The prescribing guideline was developed and 
prospectively evaluated at a single academic institution, which may limit its generalizability. The 
surgical population was predominantly white and English-speaking, which may not reflect the 
patient demographic characteristics at other institutions. We also may not have captured opioid 
refills for all patients. To obtain these data, we queried the EMR for refill data, which would 
capture refills prescribed by any provider within the University of Massachusetts network, but 
may not capture refills obtained from an outside provider. Finally, we determined the cut-points 
for our three tiers to maximize equal distribution of patients. Use of alternative cut-points could 
potentially lead to an even greater reduction in excess pills. 
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Chapter V: Conclusions 
This study shows that adoption of a simple, three-tiered, opioid prescribing guideline based on 
prior to discharge opioid consumption can dramatically reduce excessive prescribing without 
increasing prescription refills.  By tailoring discharge prescriptions to a patient’s opioid usage in 
the day prior to discharge, surgeons can better align discharge prescription quantity with a 
patient’s outpatient needs.  The success at our institution suggests that a similar effort at the state 
or national level could be successful in markedly reducing excessive prescribing by surgeons on 
larger scale. 
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Tables: 
Table 1. Patient Characteristics 
 Variable 
Before 
Guideline 
Adoption 
After 
Guideline 
Adoption 
p-value 
 (N=100) (N=101)  
Age, mean, yrs (SD) 60 (14) 64 (13) 0.05 
Female 55 (55) 55 (55) 0.94 
White 90 (90) 90 (89) 0.84 
Language   n/a 
    English NC 92 (91)  
    Spanish NC 4 (4)  
    Other NC 5 (5)  
Insurance   0.46 
    Private 62 (63) 54 (54)  
    Government † 36 (36) 45 (45)  
   None 1 (1) 1 (1)  
ASA   0.001 
    I or II 70 (70) 48 (48)  
    III or IV 30 (30) 53 (52)  
BMI, mean (SD) 27 (7) 29 (6) 0.20 
Social History    
    Current Smoker 16 (16) 13 (13) 0.53 
    Moderate/heavy Alcohol 
Use,  
    (>4 drinks/week) 
15 (15) 16 (16) 0.87 
    Recreational Drug Use 11 (11) 5 (5) 0.11 
Medical History    
    Diabetes 12 (12) 18 (18) 0.25 
    Hypertension 42 (42) 51 (51) 0.23 
    Psychiatric History ‡ 24 (24) 29 (29) 0.45 
    IBD 16 (16) 15 (15) 0.82 
    Prior abdominal surgery 60 (60) 65 (64) 0.52 
Opioid naïve § 71 (71) 69 (68) 0.68 
Current medications:    
    Benzodiazepines 20 (20) 13 (13) 0.17 
    Antidepressants 16 (16) 15 (15) 0.82 
    Gabapentin or pregabalin NC 6 (6) n/a 
Data are presented n (%) unless otherwise stated. 
NC = not collected, ASA = American Society of Anesthesiologists classification, BMI = Body 
Mass Index, IBD = Inflammatory Bowel Disease 
† Government insurance refers to Medicaid, Medicare, Massachusetts health or Veteran’s 
Administration 
‡ Diagnosis of anxiety/depression/bipolar/other 
§ Opioid naive determined by no documented prescription within 1 year pre-operatively 
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Table 2. Operative and hospitalization details 
Variable 
Before 
Guideline 
Adoption 
After 
Guideline 
Adoption 
p-value 
 (N=100) (N=101)  
Operative time in minutes, mean (SD) 191 (84) 190 (88) 0.92 
Procedure Approach   0.21 
    Open  23 (23) 27 (27)  
    Laparoscopic 74 (74) 66 (65)  
    Robotic 3 (3) 8 (8)  
Conversion to open 2 (2) 5 (5) 0.44 
Procedure type   0.68 
    Partial colectomy 75 (75) 65 (65)  
    Proctectomy  9 (9) 12 (12)  
    Total abdominal colectomy 1 (1) 3 (3)  
    Total proctocolectomy 2 (2) 4 (4)  
    Ileostomy takedown 10 (10) 13 (13)  
    Colostomy takedown 3 (3) 3 (3)  
Splenic flexure taken-down 33 (33) 26 (26) 0.19 
Ostomy creation 16 (16) 19 (19) 0.60 
Surgical drain placed 19 (19) 29 (29) 0.11 
Length of stay   0.83 
    ≤3 days 49 (49) 51 (50)  
    >3 days 51 (51) 50 (50)  
Discharge disposition   0.64 
    Home with no services 74 (74) 71 (70)  
    Home with services 26 (26) 30 (30)  
Days from discharge to follow-up, 
mean (SD) 
13 (7) 13 (4) 0.59 
Any complication † 19 (19) 28 (28) 0.14 
Any readmission‡ 2 (2) 13 (13) 0.01 
Data are presented n (%) unless otherwise stated. 
† Any complication within 30-day post-operative period 
‡ Any readmission refers to any hospital admission within 30-days post-operatively regardless of 
the attributable reason. 
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Table 3. Guideline adherence 
Variable 
Guideline 
Adherence 
Guideline 
Non-adherence 
p-value 
All Patients 86 (85.1) 15 (14.9) n/a 
Prescribing Tiers   0.44 
    Tier 1 41 (80.4) 10 (19.6)  
    Tier 2 22 (88.0) 3 (12.0)  
    Tier 3 23 (92.0) 2 (8.0)  
Operating Surgeon   0.28 
    A 10 (83.3) 2 (16.7)  
    B 23 (79.3) 6 (20.7)  
    C 38 (92.7) 3 (7.3)  
    D 15 (79.0) 4 (21.1)  
Prescriber   0.04 
    Non-surgical resident 27 (73.0) 10 (27.0)  
    Surgical resident 38 (90.5) 4 (9.5)  
    Physician assistant 21 (95.5) 1 (4.6)  
Prescribing Period   0.57 
    Month 1-2 26 (89.7) 3 (10.3)  
    Month 3-4 28 (87.5) 4 (12.5)  
    Month 5-6 32 (80.0) 8 (20.0)  
Data are presented n (%)  
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Table 4. Opioid prescription and consumption patterns 
Prescribing Tiers 
Before 
Guideline 
Adoption 
After 
Guideline 
Adoption p-value 
All patients, n 100 101   
Prescribed, mean EOP (SD) 17.5 (10.5) 10.3 (11.6) <0.001 
Consumed, mean EOP (SD) 6.7 (10.9) 5.2 (8.5) 0.27 
Excess, mean EOP (SD) 10.7 (10.2) 5.1 (7.6) <0.001 
Refills, n (%) 15 (15.0) 10(9.9) 0.27 
Tier 1, n 53 51   
Prescribed, mean EOP (SD) 15.7 (9.0) 1.8 (3.9) <0.001 
Consumed, mean EOP (SD) 2.5 (6.5) 0.2 (0.8) 0.01 
Excess, mean EOP (SD) 13.2 (9.5) 1.7 (3.8) <0.001 
Refills, n (%) 2 (3.8) 1 (2.0) 1.00 
Tier 2, n 25 25   
Prescribed, mean EOP (SD) 16.0 (7.7) 12.0 (6.5) 0.06 
Consumed, mean EOP (SD) 5.2 (6.2) 5.6 (5.3) 0.81 
Excess, mean EOP (SD) 10.8 (11.0) 6.5 (5.7) 0.09 
Refills, n (%) 4 (16.0) 2 (8.0) 0.68 
Tier 3, n 22 25   
Prescribed, mean EOP (SD) 23.7 (14.1) 25.7 (9.3) 0.56 
Consumed, mean EOP (SD) 18.6 (14.8) 15.1 (10.8) 0.35 
Excess, mean EOP (SD) 5.1 (8.8) 10.6 (10.8) 0.06 
Refills, n (%) 9 (40.1) 7 (28.0) 0.74 
EOP = Equianalgesic 5-mg Oxycodone Pills 
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Table 5. Relative reduction in opioid prescribing 
Prescribing 
Tiers 
Patients 
(n) 
Mean 
Prescribed 
Before 
Guideline 
Adoption 
(EOP) 
Mean  
Prescribed 
After 
Guideline 
Adoption 
(EOP) 
Quantity 
Would 
Have Been 
Prescribed 
Quantity 
Actually 
Prescribed 
% 
Decrease 
Tier 1 51 15.7 1.8 801 92 88.5% 
Tier 2 25 16.0 12.0 400 300 25.0% 
Tier 3 25 23.7 25.7 593 643 -8.4% 
Total    1794 1035 42.3% 
EOP = Equianalgesic 5-mg Oxycodone Pills 
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Figures 
Figure 1. Discharge prescribing guideline worksheet 
 
  
Discharge Prescribing Guideline After 
Inpatient Colorectal Surgery
This opioid prescription guideline is intended for:
• Adults who have undergone major colorectal surgery and at least 48 hours inpatient stay.
• Patients with no pre-existing outpatient opioid prescription.
Step 1: Calculate the quantity of opioid used in the 24-hours prior to discharge
Opioid Medication Total Quantity Conversion Factor * = equivalent (mg) oxycodone
PO Oxycodone __ mg x 1 = ___ mg  (a)
PO Tramadol __ mg x 0.0667 = ___ mg  (b)
PO Hydromorphone __ mg x 2.667 = ___ mg  (c)
IV Fentanyl __ micrograms x 0.2 = ___ mg  (d)
IV Hydromorphone __ mg x 13.333 = ___ mg  (e)
IV Morphine __ mg x 2 = ___ mg  (f)
* Adapted from CMS Opioid Conversion Factors                                   (g) Sum (a-f) = Total (mg) oxycodone equivalent
Step 2: Determine prescribing 
Tier (g)
(a) Tier 1 ( 0mg oxycodone equivalent) 
(b) Tier 2     ( ≤15 mg oxycodone equivalent) 
(c) Tier 3     ( >15 mg oxycodone equivalent)
Step 3: Prescribe according to prescribing Tier (determined in Step 2).
Prescribing Tiers
Choose pain medication (a) Tier 1 (b) Tier 2 (c) Tier 3
a  Oxycodone 5mg pills
(total mg oxycodone) 
0 pills
(0 mg)
12 pills
(60 mg)
30 pills
(150 mg)
b  Hydrocodone 5mg pills
(total mg hydrocodone)
0 pills
(0 mg)
18 pills
(90 mg)
45 pills
(225 mg)
Tramadol 50mg pills
(total mg tramadol)
0 pills
(0 mg)
18 pills
(900 mg)
45 pills
(2250 mg)
Hydromorphone 2mg pills
(total mg hydromorphone)
0 pills
(0 mg)
~11 pills
(22.5 mg)
~28 pills
(56.2 mg)
a or equivalent (eg. Percocet)
b or equivalent (eg. Norco, Vicodin)
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Figure 2. Study Flow Diagram 
 
  
25 (25%)
Colon or Rectal Resections and Ostomy Reversals
Patients analyzed
(n = 100)
53 (53%)
Excluded (n = 57)
5  Emergent cases
12  Discharge to inpatient facility 
4 Opioid exposure  within <30 days or chronic use
0  length of stay less than 48 hours
36  Missing opioid consumption data
22 (22%)
* Tiers based on opioid consumption 24-hours prior to 
discharge
Before Guideline
(n = 157)
After Guideline
(n = 155)
Excluded (n = 54)
16  Emergent cases
3  Discharge to inpatient facility 
16  Opioid exposure  within <30 days or chronic use
0  Length of stay less than 48 hours
20  Missing opioid consumption data
Patients analyzed
(n = 101)
51 (50%)
25 (25%)
25 (25%)
Tier 1*
Tier 2
Tier 3
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Figure 3. Comparison of equi-analgesic 5-milligram oxycodone pills (EOP) prescribed and 
consumed according to prescribing tiers. 
 
Figure 3. The box-plot shows the distribution of opioid quantities prescribed and consumed for 
each prescribing tier. The plot on the left shows the distribution for the historical data collected 
before guideline adoption and the plot on the right show the distribution of data from the present 
study after guideline adoption.  After guideline adoption, prescription quantity was significantly 
reduced for Tier 1, but not for Tier 2 or 3.  There was no change in consumption for any prescribing 
tier.  
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APPENDICES 
Appendix (i) - Hospital Administered Medications 
   
After 
Guideline 
Adoption 
Phase of Care Medication N=101 
Post-anesthesia care unit   
 IV ketorolac 43 (43) 
 PO Tylenol 45 (45) 
 gabapentin 6 (6) 
 IV Tylenol 0 (0) 
Post-operative day 1   
 IV opioid 94 (93) 
 PO Tylenol 94 (93) 
 IV ketorolac 65 (64) 
 gabapentin 22 (22) 
 alvimopan 17 (17) 
 TD lidocaine  14 (14) 
 PO opioid 8 (8) 
 PO NSAID 2 (2) 
 epidural 0 (0) 
 IV Tylenol 0 (0) 
Data are presented as n (%). 
IV = intravenous, PO = by mouth, TD = transdermal, NSAID = non-steroidal anti-inflammatory 
drug 
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Appendix (ii) – Discharge prescriptions 
Prescription Total 
Before 
Guideline 
Adoption 
After 
Guideline 
Adoption 
p-value 
 N=201 N=100 N=101  
Non-opioid Prescribed     
    Tylenol 174 (87) 83 (83) 91 (90) 0.15 
    Ibuprofen 52 (26) 16 (16) 36 (36) 0.002 
    Naproxen 0 (0) 0 (0) 0 (0) 1.00 
    Gabapentin 0 (0) 0 (0) 0 (0) 1.00 
Opioid Prescribed    <0.0001 
    None 51 (25) 9 (9) 42 (42)  
    Oxycodone 137 (68) 84 (84) 53 (53)  
    Hydromorphone 3 (1) 1 (1) 2 (2)  
    Hydrocodone 1 (0) 1 (1) 0 (0)  
    Tramadol 9 (4) 5 (5) 4 (4)  
Combo Pill † 3 (1) 3 (3) 0 (0) 0.12 
Data are presented as n (%). 
† Combo pill refers to a prescription opioid formulation in combination with non-steroidal anti-
inflammatory drug 
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Appendix (iii). Post-operative Complications 
Complication Total 
Before 
Guideline 
Adoption 
After 
Guideline 
Adoption 
p-value 
 N=201 N=100 N=101  
Any complication * 47 (23) 19 (19) 28 (28) 0.14 
    Ileus 22 (11) 13 (13) 9 (9) 0.38 
    UTI 4 (2) 1 (1) 3 (3) 0.62 
    Urinary retention 6 (3) 3 (3) 3 (3) 1.00 
    SSI 10 (5) 4 (4) 6 (6) 0.75 
    ICU admission 2 (1) 1 (1) 1 (1) 1.00 
    Reoperation 2 (1) 1 (1) 1 (1) 1.00 
    Sepsis 1 (0) 1 (1) 0 (0) 0.50 
    DVT 1 (0) 1 (1) 0 (0) 0.50 
    Renal failure 1 (0) 0 (0) 1 (1) 1.00 
    Other 13 (7) 3 (3) 10 (10) 0.08 
    High ostomy output 2 (1) 0 (0) 2 (2) 0.50 
    OSI 1 (0) 0 (0) 1 (1) 1.00 
    Anastomotic leak 1 (0) 1 (1) 0 (0) 0.50 
30-day readmission† 15 (7) 2 (2) 13 (13) 0.01 
Data are presented as n (%). 
UTI = urinary tract infection, SSI = surgical site infection, ICU = intensive care unit, DVT = 
deep venous thrombosis, OSI = organ space infection 
* Any-complication refers to number of patients with a reported complication within 30-days 
† Re-admission refers to any hospital admission within 30-days post-operatively regardless of 
the attributable reason. 
 
